Anticlotting drug found to be safe in sickle cell patientsOctober 12, 2007CHAPEL HILL - An intravenous "blood thinner" widely used in patients with acute coronary syndromes and during coronary artery stent placement appears to be safe in patients with sickle cell disease and may have beneficial anti-inflammatory effects, a small study at the University of North Carolina at Chapel Hill School of Medicine has found. "We have tested a potentially promising drug in sickle cell patients, and the drug appears to be well tolerated. This gives us the impetus to go ahead with further studies of eptifibatide in these patients," said Dr. Leslie V. Parise, department chair and professor of biochemistry and biophysics at the UNC-Chapel Hill School of Medicine. The hallmark of sickle cell disease is malformed red blood cells that can cause sudden painful episodes when they block small blood vessels. However, sickle cell patients are also at increased risk of developing multiple other complications, including strokes, lung complications and pulmonary hypertension. The most frequent manifestations of sickle cell disorders are anemia and pain episodes. The episodic exacerbation of pain, often called "crises," is unpredictable and may occur often in some patients. The only drug presently approved for the treatment of sickle cell disease is hydroxyurea, which has been shown to reduce the frequency of painful episodes. Parise emphasized the need for further study. "We did not test this drug in patients who are in crisis, and we cannot recommend that doctors prescribe this drug for sickle cell patients at this time," she said. The results of the study were published online (Oct. 6) in the British Journal of Haematology. The researchers gave intravenous infusions of eptifibatide (brand name Integrilin) to four patients with sickle cell anemia who were not experiencing pain episodes. "They did well clinically. They did not experience any deleterious changes in their blood tests or have a pain episode," said coauthor Dr. Kenneth I. Ataga, assistant professor of medicine at UNC-Chapel Hill. In the current study, blood tests showed that while the patients' liver, kidney and other functions remained at baseline, several indicators of inflammation decreased, including levels of a protein called CD40L known to play a role in inflammation and in blood clotting. Previous studies conducted by Sheritha Lee a graduate student in Parise's lab showed that patients with sickle cell disease have CD40L levels that are as much as 30 times higher than in patients without the disease. Eptifibatide's known ability to decrease CD40L led the researchers to study whether the drug might help sickle cell patients. University of North Carolina at Chapel Hill |
|||||||||||||||||||||
| Related Sickle Cell Current Events and Sickle Cell News Articles Causative gene of a rare disorder discovered by sequencing only protein-coding regions of genome For the first time, scientists have successfully used a method called exome sequencing to quickly discover a previously unknown gene responsible for a mendelian disorder. Drug shows promise in treating dangerous complication of erectile disorder Thousands of men are afflicted with an embarrassing and painful condition that triggers spontaneous, long-lasting erections. There are limited treatment options, but a solution could be on the way thanks to new research at The University of Texas Health Science Center at Houston. That '4 hour erection': new discovery may help prevent a complication of priapism For men coping with painful erections lasting for long periods of time, or priapism, new research published online in The FASEB Journal (http://www.fasebj.org) offers hope. Governor recognizes stem cell research at Einstein Albert Einstein College of Medicine of Yeshiva University hosted a roundtable discussion on stem cell research with New York Governor David A. Paterson today. Males May Experience Greater Physical Pain Due To Lower Levels Of A Key Protein, Endothelin Agonizing physical pain, known as vaso-occlusive pain, can afflict children who have sickle cell disease (SCD). Faster, cheaper way to find disease genes in human genome passes initial test University of Washington (UW) researchers have successfully developed a novel genome-analysis strategy for more rapid, lower cost discovery of possible gene-disease links. Mother's immune system may block fetal treatments for blood diseases Pediatric researchers have resolved an apparent contradiction in the field of prenatal cell transplantation- a medical approach that holds future promise in correcting sickle cell disease and other serious congenital blood disorders. NHLBI stops study of pulmonary hypertension treatment in sickle cell patients The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health has stopped a clinical trial testing a drug treatment for pulmonary hypertension in adults with sickle cell disease nearly one year early due to safety concerns. Children's Hospital Oakland scientists first to discover new source for harvesting stem cells A groundbreaking study conducted by Children's Hospital & Research Center Oakland is the first to reveal a new avenue for harvesting stem cells from a woman's placenta, or more specifically the discarded placentas of healthy newborns. Embryo's heartbeat drives blood stem cell formation Biologists have long wondered why the embryonic heart begins beating so early, before the tissues actually need to be infused with blood. More Sickle Cell Current Events and Sickle Cell News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||